TY - JOUR
T1 - A prospective, randomized clinical study comparing accelerated corneal collagen crosslinking with 5% NaCl hypertonic saline for bullous keratopathy in Asian eyes
AU - Kasai, Kozue
AU - Kato, Naoko
AU - Den, Seika
AU - Konomi, Kenji
AU - Shinzawa, Megumi
AU - Shimazaki, Jun
N1 - Publisher Copyright:
© 2019 the Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Background:We compared the clinical outcomes of accelerated corneal collagen crosslinking (CXL) and 5% NaCl hypertonic saline (HS) for the treatment of symptomatic bullous keratopathy (BK).Methods:A randomized controlled trial was held at Department of Ophthalmology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan. Twenty-three eyes of 23 consecutive patients with symptomatic BK were enrolled. The etiology of BK included pseudophakic BK, previous keratoplasty, previous endotheliitis, previous glaucoma surgery, trauma, herpes infection, as well as unknown causes. Eleven eyes received epi-off accelerated CXL (with epithelial abrasion and 18mW/cm2 ultraviolet A irradiation for 5minutes) and 12 eyes received HS instillation. In addition to the usual ophthalmic examination, the best-corrected visual acuity (BCVA) and central corneal thickness (CCT) were determined. The CCT was measured using anterior segment optical coherence tomography before and up to 6 months after treatments. Subjective symptoms of pain, blurred vision, photophobia, and irritation were also recorded.Results:The follow-up was completed for all patients in the CXL group. However, 6 patients in the HS group requested CXL treatments after 3 months. The BCVA was not significantly changed during the study periods in both groups. The CCT was significantly thinner in the CXL group compared to the HS group at 1 and 6 months (P=.015 and 0.144, respectively). Among the subjective symptoms recorded, irritation was significantly lower in the CXL group at 1 month (P=.013).Conclusions:Accelerated CXL may produce transient improvement in pain and corneal edema in patients with BK.
AB - Background:We compared the clinical outcomes of accelerated corneal collagen crosslinking (CXL) and 5% NaCl hypertonic saline (HS) for the treatment of symptomatic bullous keratopathy (BK).Methods:A randomized controlled trial was held at Department of Ophthalmology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan. Twenty-three eyes of 23 consecutive patients with symptomatic BK were enrolled. The etiology of BK included pseudophakic BK, previous keratoplasty, previous endotheliitis, previous glaucoma surgery, trauma, herpes infection, as well as unknown causes. Eleven eyes received epi-off accelerated CXL (with epithelial abrasion and 18mW/cm2 ultraviolet A irradiation for 5minutes) and 12 eyes received HS instillation. In addition to the usual ophthalmic examination, the best-corrected visual acuity (BCVA) and central corneal thickness (CCT) were determined. The CCT was measured using anterior segment optical coherence tomography before and up to 6 months after treatments. Subjective symptoms of pain, blurred vision, photophobia, and irritation were also recorded.Results:The follow-up was completed for all patients in the CXL group. However, 6 patients in the HS group requested CXL treatments after 3 months. The BCVA was not significantly changed during the study periods in both groups. The CCT was significantly thinner in the CXL group compared to the HS group at 1 and 6 months (P=.015 and 0.144, respectively). Among the subjective symptoms recorded, irritation was significantly lower in the CXL group at 1 month (P=.013).Conclusions:Accelerated CXL may produce transient improvement in pain and corneal edema in patients with BK.
KW - bullous keratopathy
KW - corneal cross-linking (CXL)
KW - corneal thickness
KW - subjective symptoms
UR - http://www.scopus.com/inward/record.url?scp=85076977503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076977503&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000018256
DO - 10.1097/MD.0000000000018256
M3 - Article
C2 - 31860972
AN - SCOPUS:85076977503
SN - 0025-7974
VL - 98
JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries
JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries
IS - 51
M1 - e18256
ER -